Event-Driven Stocks

Jazz Pharmaceuticals plc

JAZZNasdaq

Healthcare · Pharmaceutical Preparations · L2 · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 3 good● 2 warningdetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$4.27B$4.07B$3.83B$3.66B$3.09B$2.36B
Operating income−$430.2M$716.6M$578.6M−$65.5M$170.3M$378.1M
Net income−$356.1M$560.1M$414.8M−$224.1M−$329.7M$238.6M
Total assets$11.66B$12.01B$11.39B$10.84B$12.30B$6.54B
Total liabilities——————
Equity$4.32B$4.09B$3.74B$3.09B$3.97B$3.66B
EPS (diluted)$-5.84$8.65$6.10$-3.58$-5.52$4.22
Shares out.60.7M62.3M63.3M61.7M56.3M56.1M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−10.1%
Net margin
−8.3%
Return on equity
−8.2%
Return on assets
−3.1%
Return on capital (ROCE)
−4.6%
Liabilities / assets
—
Debt / equity
—
Book value / share
$71.11
Revenue growth (YoY)
4.9%
Net income growth (YoY)
−163.6%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Accruals / assets
−14.7%clean
Piotroski F-Score
4/8mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
57
/ 100
Profitability 0Growth 50Catalyst 33Earnings quality 100Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 warning● 3 good
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Revenue is growing year-over-year
  • Positive operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

FDA-approved drugs

openFDA · most recent
  • XYWAVJul 21, 2020
  • ZEPZELCAJun 15, 2020
  • LUVOXApr 14, 2008
  • FAZACLO ODTFeb 10, 2004

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20264.8M4.7-4.7%
Apr 30, 20265.1M5.3-2.9%
Apr 15, 20265.2M6.0-19.7%
Mar 31, 20266.5M8.0+5.9%
Mar 13, 20266.2M7.6+2.8%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (4)